Karyopharm Therapeutics Inc. has announced the completion of enrollment in its Phase 3 SENTRY trial, which evaluates the efficacy of selinexor in combination with ruxolitinib for patients with JAKi-naïve myelofibrosis. This pivotal trial aims to assess the potential of this combination therapy to become the first approved treatment of its kind for this rare blood cancer.
Richard Paulson, President and CEO of Karyopharm, expressed optimism regarding the trial’s implications, stating that the combination could redefine treatment standards for myelofibrosis. The trial enrolled 353 patients and focuses on key endpoints, including spleen volume response and symptom relief, which are critical for patient quality of life.
Myelofibrosis currently has limited treatment options, primarily JAK inhibitors, which often lead to complications such as anemia. The successful outcome of the SENTRY trial could provide new hope and therapeutic avenues for the approximately 20,000 patients in the U.S. and 17,000 in the EU suffering from this condition, highlighting the urgent need for innovative therapies in this space.
